Natural peptides to drugs - fourth international congress.
The Natural Peptides to Drugs congress, held in Zermatt, Switzerland, included topics covering new therapeutic developments in the field of peptide- and protein-based drugs derived from natural products. This conference report highlights selected presentations on drug discovery from natural peptides, natural peptide-based drugs in preclinical and clinical development, and peptide candidates. Investigational drugs discussed include novel small peptides from KAI Pharmaceuticals Inc, XEP-018 (Atheris Laboratories), MKC-253 (MannKind Corp), AEZS-108 (AEterna Zentaris Inc) and XG-102 (Auris Medical AG/Xigen SA).
Leone-Bay
Andrea
A
MannKind Corp, 1 Casper Street, Danbury, CT 06810, USA. aleone-bay@mannkindcorp.com
D000818:Animals; D001688:Biological Products / Q000494:pharmacology*; D015195:Drug Design; D055808:Drug Discovery; D015507:Drugs, Investigational; D006801:Humans; D019151:Peptide Library; D010455:Peptides / Q000494:pharmacology*; D008517:Phytotherapy; D028321:Plant Preparations / Q000494:pharmacology; D013678:Technology, Pharmaceutical
D001688:Biological Products; D015507:Drugs, Investigational; D019151:Peptide Library; D010455:Peptides; D028321:Plant Preparations